In 2004, clinical studies
involving Epidural Analgesia using our CompuFlo® system
technology were conducted at the University of Texas Health
Science Center at Houston under the guidance of Dr. Oscar
Ghelber, Assistant Professor Anesthesiology.
Results of the initial study revealed that
the CompuFlo system detects pressure changes as
the needle penetrates human tissue with differing characteristics. Researchers
confirmed that the CompuFlo system:
Clearly and successfully
identified the epidural space in 100% of the test subjects.
identified false readings.
Provides precise and objective
Allows anesthesiologists to use both hands to
advance and direct the needle.
The study concluded that objective identification of the
epidural space could potentially decrease the incidence of
complications, increase the success rate of the procedure
and enhance patient safety.
In a follow-on study completed in early 2005, Dr. Ghelber’s
team reconfirmed that the CompuFlo system reliably
identified, in all cases, the pressure characteristics of
different tissues, including the pressure that characterizes
the epidural space. Moreover, it was determined that
the location of the needle can be easily determined within
The application benefits of Milestone’s CompuFlo-based
Epidural Injection System are numerous and well
defined, and include:
materially reducing, and possibly
eliminating, existing medical risks and complications associated
with administering epidurals;
improving patient safety and
reducing liability to medical care providers/institutions;
reducing malpractice clams and related insurance premiums